Detalhe da pesquisa
1.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Ann Oncol
; 34(2): 200-211, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423745
2.
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
Ann Oncol
; 24(5): 1253-61, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23233651
3.
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
Ann Oncol
; 24(3): 702-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23108952
4.
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel.
Breast
; 72: 103582, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769521
5.
Multimodality treatment for localized gastro-oesophageal cancer.
Ann Oncol
; 21 Suppl 7: vii286-93, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20943630
6.
Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer.
Oncology
; 79(1-2): 150-8, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21150230
7.
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.
Ann Oncol
; 20(9): 1529-1534, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19474114
8.
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.
Eur J Cancer
; 49(9): 2116-25, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23481512